Model Medicines

GALILEO is Model Medicines’ multimodal AI drug discovery platform, integrating biological data, machine learning, and drug design to discover novel therapeutics.

Fierce Biotech profiles Model Medicines’ differentiated approach to AI drug discovery, highlighting how the company brings together data science, computer science, chemistry, biology, and drug development expertise to identify first-in-class therapeutic candidates.

Head of Platform and Machine Learning, Tyler Umansky, to deliver Day 1 session “Breaking the Throughput Barrier” and join Day 2 panel “From Target to Therapy: Navigating the Drug Discovery Pipeline”

Oral presentation highlights first-in-class Thumb-1 polymerase inhibitor with broad-spectrum single-agent efficacy against influenza, RSV, SARS-CoV-2, HCV, HBV, and HDV

CEO Daniel Haders, PhD, will discuss upcoming catalyst events for MDL-001, targeting the RdRp Thumb-1 site for ILI and chronic hepatitis, and MDL-4102, targeting BRD4 for cancers and inflammatory diseases.

Model Medicines handles scientific, partnership, investment, media, and general inquiries related to its AI-driven drug discovery work.

Model Medicines engineers first-in-class small molecules against biological choke points, using AI to advance pipeline-in-a-pill therapeutics across high-impact diseases.

Model Medicines describes how it collects, uses, protects, and manages personal information submitted through its website, forms, updates, and communications.